Mr James Downie, CEO, presented on the topic 'Moving towards value based funding' at the Healthcare reform, funding and innovation conference, hosted by AventEdge on 27 June 2017.
Mr James Downie, CEO, presented on the topic 'Emergency care costing study and classification development' at the 9th Annual Emergency Department Management Conference, hosted by informa on 31 July 2017.
Mr James Downie, CEO, presented on the topic 'Independent Hospital Pricing Authority Update' at the HBN/CHASAN Steering Committee, hosted by Catholic Negotiating Alliance on 15 May 2017.
Mr James Downie, CEO, presented on the topic 'Moving towards value based funding' at the 2017 Activity-Based Funding Conference, hosted by the Health Service Executive, Ireland on 11 May 2017.
Mr James Downie, CEO, presented on the topic 'IHPA 2017 and beyond' at the Enhancing Performance & Efficiency in Paediatric Care - CHA Annual Benchmarking Forum, hosted by Children's Healthcare Australasia on 25 May 2017.
Jennifer Nobbs, Executive Director, Activity Based Funding, presented on the topic 'IHPA and Activity Based Funding' at a meeting of the Australian Stroke Coalition on 27 June 2017.
Mr James Downie, CEO, presented on the topic 'Emergency care costing study and classification development' at the 9th Annual Emergency Department Management Conference, hosted by informa on 31 July 2017.
Mr James Downie, CEO, presented on the topic 'Independent Hospital Pricing Authority Update' at the HBN/CHASAN Steering Committee, hosted by Catholic Negotiating Alliance on 15 May 2017.
Mr James Downie, CEO, presented on the topic 'Moving towards value based funding' at the 2017 Activity-Based Funding Conference, hosted by the Health Service Executive, Ireland on 11 May 2017.
Mr James Downie, CEO, presented on the topic 'IHPA 2017 and beyond' at the Enhancing Performance & Efficiency in Paediatric Care - CHA Annual Benchmarking Forum, hosted by Children's Healthcare Australasia on 25 May 2017.
Jennifer Nobbs, Executive Director, Activity Based Funding, presented on the topic 'IHPA and Activity Based Funding' at a meeting of the Australian Stroke Coalition on 27 June 2017.
What Happens After Your Device is Approved? Collecting Data in the Real WorldMedpace
In this workshop, Medpace will discuss key considerations for generating real-world evidence and how to apply critical insights in order to drive late-stage clinical research. To listen to this presentation, visit https://vimeo.com/168768256
Learn how to leverage effective strategies for global drug development, including expedited regulatory pathways, personalized medicines and genomics. View the full presentation from PAREXEL Consulting experts.
Real-World Data – What’s Next? by Michael Seewald, AstraZeneca for mHealth Is...Levi Shapiro
Presentation by Michael Seewald, Michael Seewald, Ph.D.
Global Head Evidence, AstraZeneca Biopharmaceuticals for mHealth Israel, October 19th, 2021.
Real-World Data is able to uncover local unmet medical need – Call to action to build Learning Healthcare Systems. Significant Variations in Care and Large Potential for Improvement. Real-World Data helps to benchmark efficient use of resources and detect “waste”. Healthcare systems need to address the problem of waste. But fundamental change is hard, and progress slow. Outcomes Transparency Improves ComplianceExample: Swedish myocardial infarction registry. Outcomes Transparency Improves Compliance. Example: Swedish myocardial infarction registry. Improving Outcomes and Creating Value will continue to guide Learning Healthcare Systems- enabled by RWD. Four technological trends as accelerators on our path. Empowered patients- Molecular screening and 24/7 monitoring driving a step change in diagnosis. Algorithmic decision-making: Artificial intelligence supports physician intelligence. Evidence-generating healthcare systemsLive insights on clinical efficacy from digital monitoring. 360° care delivery. Home replaces hospital via digital therapeutics and on-demand remote support. AstraZeneca Areas of Partnering Interest: (https://www.astrazeneca.com/partnering/our-areas-of-partnering-interest.html).
What's Next in RWE_Amy Rudolph_Novartis_mHealth IsraelLevi Shapiro
Overview of the
- Healthcare ecosystem complexity increasing rapidly
- Pharma industry is facing a crisis: trends shaping the industry
- RWE complements RCTs and captures implementation of innovation
- RWE is one component of the integrated evidence needed for stakeholders
- Integrated Evidence: Optimizing patient access
- Integrated Evidence: Label expansion
- Maximizing the value of data requires a scalable platform and expertise
Health IT Summit Boston 2014 – Case Study “Beyond MU Stage 2: Maximizing the value of your HER” with Larry Garber, Medical Director of Informatics, Reliant Medical Group
Seamless Journey from Population Health to Precision MedicineOrion Health
Precision medicine is happening now! Join us as we examine the opportunities to leverage your initial core data sets and prepare for new data types to deliver real-time population health and precise medicine.
This webinar will demonstrate how modern healthcare organizations (HCO) are expanding clinical integration and upgrading to higher performing technology stacks on their journey to the omics-based and real-time delivery of precision medicine.
We’ll chat with Dr. Chris Hobson, CMO and CPO at Orion Health, Doctor Dylan Mordaunt, Clinical Director Research at Orion Health, and with Orion Health’s Executive Vice President of Product and Strategy, Dave Bennett about the importance of real-time data mining and re-mining, and which new computational tools and techniques you need to meet your population health goals and future proof your organization for the delivery of precision medicine.
In this webinar, we will explain:
How new models of medicine (e.g., molecular medicine, value-based medicine, etc.) are driving the immediate need for patient-specific decision support assistance
How existing and new data sets can be leveraged with integrated and real-time analytics (e.g., family history, pharmacogenics) for immediate reduction in adverse events and improved outcomes
How innovative organizations are answering this demand with high-performing technology
Understanding Regulatory and Payer Requirements Throughout CommercializationPAREXEL International
Learn about regulator and payer evidence requirements as well as other key market access considerations in drug development. Read this presentation from PAREXEL Consulting experts.
What Happens After Your Device is Approved? Collecting Data in the Real WorldMedpace
In this workshop, Medpace will discuss key considerations for generating real-world evidence and how to apply critical insights in order to drive late-stage clinical research. To listen to this presentation, visit https://vimeo.com/168768256
Learn how to leverage effective strategies for global drug development, including expedited regulatory pathways, personalized medicines and genomics. View the full presentation from PAREXEL Consulting experts.
Real-World Data – What’s Next? by Michael Seewald, AstraZeneca for mHealth Is...Levi Shapiro
Presentation by Michael Seewald, Michael Seewald, Ph.D.
Global Head Evidence, AstraZeneca Biopharmaceuticals for mHealth Israel, October 19th, 2021.
Real-World Data is able to uncover local unmet medical need – Call to action to build Learning Healthcare Systems. Significant Variations in Care and Large Potential for Improvement. Real-World Data helps to benchmark efficient use of resources and detect “waste”. Healthcare systems need to address the problem of waste. But fundamental change is hard, and progress slow. Outcomes Transparency Improves ComplianceExample: Swedish myocardial infarction registry. Outcomes Transparency Improves Compliance. Example: Swedish myocardial infarction registry. Improving Outcomes and Creating Value will continue to guide Learning Healthcare Systems- enabled by RWD. Four technological trends as accelerators on our path. Empowered patients- Molecular screening and 24/7 monitoring driving a step change in diagnosis. Algorithmic decision-making: Artificial intelligence supports physician intelligence. Evidence-generating healthcare systemsLive insights on clinical efficacy from digital monitoring. 360° care delivery. Home replaces hospital via digital therapeutics and on-demand remote support. AstraZeneca Areas of Partnering Interest: (https://www.astrazeneca.com/partnering/our-areas-of-partnering-interest.html).
What's Next in RWE_Amy Rudolph_Novartis_mHealth IsraelLevi Shapiro
Overview of the
- Healthcare ecosystem complexity increasing rapidly
- Pharma industry is facing a crisis: trends shaping the industry
- RWE complements RCTs and captures implementation of innovation
- RWE is one component of the integrated evidence needed for stakeholders
- Integrated Evidence: Optimizing patient access
- Integrated Evidence: Label expansion
- Maximizing the value of data requires a scalable platform and expertise
Health IT Summit Boston 2014 – Case Study “Beyond MU Stage 2: Maximizing the value of your HER” with Larry Garber, Medical Director of Informatics, Reliant Medical Group
Seamless Journey from Population Health to Precision MedicineOrion Health
Precision medicine is happening now! Join us as we examine the opportunities to leverage your initial core data sets and prepare for new data types to deliver real-time population health and precise medicine.
This webinar will demonstrate how modern healthcare organizations (HCO) are expanding clinical integration and upgrading to higher performing technology stacks on their journey to the omics-based and real-time delivery of precision medicine.
We’ll chat with Dr. Chris Hobson, CMO and CPO at Orion Health, Doctor Dylan Mordaunt, Clinical Director Research at Orion Health, and with Orion Health’s Executive Vice President of Product and Strategy, Dave Bennett about the importance of real-time data mining and re-mining, and which new computational tools and techniques you need to meet your population health goals and future proof your organization for the delivery of precision medicine.
In this webinar, we will explain:
How new models of medicine (e.g., molecular medicine, value-based medicine, etc.) are driving the immediate need for patient-specific decision support assistance
How existing and new data sets can be leveraged with integrated and real-time analytics (e.g., family history, pharmacogenics) for immediate reduction in adverse events and improved outcomes
How innovative organizations are answering this demand with high-performing technology
Understanding Regulatory and Payer Requirements Throughout CommercializationPAREXEL International
Learn about regulator and payer evidence requirements as well as other key market access considerations in drug development. Read this presentation from PAREXEL Consulting experts.
NVTC Capital Health Tech Summit: Dr. Shannon KeynoteAlexa Magdalenski
The 2017 Capital Health Tech Summit took place on June 15, 2017 at the Inova Center for Personalized Health. Dr. Richard Shannon, Executive Vice President, Health Affairs, University of Virginia provided the Summit's second keynote.
Edifecs: Demonstrating who you are in CJREdifecs Inc
A hands-on approaches for hospitals to strategically align orthopedic surgeons and post-acute providers under CJR. This Presentation focuses on tools that providers can use to help manage their performance to be successful under the new value-based environment.
Advanced Laboratory Analytics — A Disruptive Solution for Health SystemsViewics
As US healthcare systems grapple with the recent upheavals in care payment and delivery, they are turning to advanced analytics as their “central nervous systems” for driving care and financial performance.
Laboratory information — spanning chemistry, pathology, microbiology and molecular testing, for example — is among the best sources of data for these advanced analytics, including clinician decision support, predictive analytics, population health management, and personalized medicine. When strategically harnessed and integrated to create a patient-centric lab data lake, laboratory information can form an affordable yet competitively powerful advanced analytics solution well suited for many health systems — i.e., a disruptive option.
L. Eleanor J. Herriman, MD, MBA, Chief Medical Informatics Officer of Viewics, explains why laboratory data should be a core strategic component for achieving success in value-based healthcare.
Testing Telehealth Solutions for Post Acute CareVSee
Telehealth Failures & Secrets to Success Conference 2017 by VSee
Speaker: Tomi Ryba & Margaret Wilmer
Senior Director of Integrated Care of El Camino Hospital
More info at: vsee.com/conference
The Thailand HiT reports that sustained political commitment to the health of the population since the 1970s has resulted in significant investment in health infrastructure, in particular primary health care, district and provincial referral hospitals, and strengthened the overall functioning of the Thai health system. After Thailand achieved universal health coverage in 2002, public expenditure on health significantly increased from 63% to 77% and out-of-pocket expense was reduced from 27.2% to 12.4% of the total health spending in 2011.
Dave Cronin (HSCIC, Business Change Lead, Data Linkage and Extract Service) provides an overview of the Data Linkage and Extract Service. He also discusses a new ground breaking development programme; making available new datasets, subject to robust information governance controls.
Similar to Moving towards value based funding (20)
QA Paediatric dentistry department, Hospital Melaka 2020Azreen Aj
QA study - To improve the 6th monthly recall rate post-comprehensive dental treatment under general anaesthesia in paediatric dentistry department, Hospital Melaka
Antibiotic Stewardship by Anushri Srivastava.pptxAnushriSrivastav
Stewardship is the act of taking good care of something.
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
WHO launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2015 to fill knowledge gaps and inform strategies at all levels.
ACCORDING TO apic.org,
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
ACCORDING TO pewtrusts.org,
Antibiotic stewardship refers to efforts in doctors’ offices, hospitals, long term care facilities, and other health care settings to ensure that antibiotics are used only when necessary and appropriate
According to WHO,
Antimicrobial stewardship is a systematic approach to educate and support health care professionals to follow evidence-based guidelines for prescribing and administering antimicrobials
In 1996, John McGowan and Dale Gerding first applied the term antimicrobial stewardship, where they suggested a causal association between antimicrobial agent use and resistance. They also focused on the urgency of large-scale controlled trials of antimicrobial-use regulation employing sophisticated epidemiologic methods, molecular typing, and precise resistance mechanism analysis.
Antimicrobial Stewardship(AMS) refers to the optimal selection, dosing, and duration of antimicrobial treatment resulting in the best clinical outcome with minimal side effects to the patients and minimal impact on subsequent resistance.
According to the 2019 report, in the US, more than 2.8 million antibiotic-resistant infections occur each year, and more than 35000 people die. In addition to this, it also mentioned that 223,900 cases of Clostridoides difficile occurred in 2017, of which 12800 people died. The report did not include viruses or parasites
VISION
Being proactive
Supporting optimal animal and human health
Exploring ways to reduce overall use of antimicrobials
Using the drugs that prevent and treat disease by killing microscopic organisms in a responsible way
GOAL
to prevent the generation and spread of antimicrobial resistance (AMR). Doing so will preserve the effectiveness of these drugs in animals and humans for years to come.
being to preserve human and animal health and the effectiveness of antimicrobial medications.
to implement a multidisciplinary approach in assembling a stewardship team to include an infectious disease physician, a clinical pharmacist with infectious diseases training, infection preventionist, and a close collaboration with the staff in the clinical microbiology laboratory
to prevent antimicrobial overuse, misuse and abuse.
to minimize the developme
How many patients does case series should have In comparison to case reports.pdfpubrica101
Pubrica’s team of researchers and writers create scientific and medical research articles, which may be important resources for authors and practitioners. Pubrica medical writers assist you in creating and revising the introduction by alerting the reader to gaps in the chosen study subject. Our professionals understand the order in which the hypothesis topic is followed by the broad subject, the issue, and the backdrop.
https://pubrica.com/academy/case-study-or-series/how-many-patients-does-case-series-should-have-in-comparison-to-case-reports/
Struggling with intense fears that disrupt your life? At Renew Life Hypnosis, we offer specialized hypnosis to overcome fear. Phobias are exaggerated fears, often stemming from past traumas or learned behaviors. Hypnotherapy addresses these deep-seated fears by accessing the subconscious mind, helping you change your reactions to phobic triggers. Our expert therapists guide you into a state of deep relaxation, allowing you to transform your responses and reduce anxiety. Experience increased confidence and freedom from phobias with our personalized approach. Ready to live a fear-free life? Visit us at Renew Life Hypnosis..
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfSachin Sharma
Pediatric nurses play a vital role in the health and well-being of children. Their responsibilities are wide-ranging, and their objectives can be categorized into several key areas:
1. Direct Patient Care:
Objective: Provide comprehensive and compassionate care to infants, children, and adolescents in various healthcare settings (hospitals, clinics, etc.).
This includes tasks like:
Monitoring vital signs and physical condition.
Administering medications and treatments.
Performing procedures as directed by doctors.
Assisting with daily living activities (bathing, feeding).
Providing emotional support and pain management.
2. Health Promotion and Education:
Objective: Promote healthy behaviors and educate children, families, and communities about preventive healthcare.
This includes tasks like:
Administering vaccinations.
Providing education on nutrition, hygiene, and development.
Offering breastfeeding and childbirth support.
Counseling families on safety and injury prevention.
3. Collaboration and Advocacy:
Objective: Collaborate effectively with doctors, social workers, therapists, and other healthcare professionals to ensure coordinated care for children.
Objective: Advocate for the rights and best interests of their patients, especially when children cannot speak for themselves.
This includes tasks like:
Communicating effectively with healthcare teams.
Identifying and addressing potential risks to child welfare.
Educating families about their child's condition and treatment options.
4. Professional Development and Research:
Objective: Stay up-to-date on the latest advancements in pediatric healthcare through continuing education and research.
Objective: Contribute to improving the quality of care for children by participating in research initiatives.
This includes tasks like:
Attending workshops and conferences on pediatric nursing.
Participating in clinical trials related to child health.
Implementing evidence-based practices into their daily routines.
By fulfilling these objectives, pediatric nurses play a crucial role in ensuring the optimal health and well-being of children throughout all stages of their development.
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Dr. David Greene Arizona
As we watch Dr. Greene's continued efforts and research in Arizona, it's clear that stem cell therapy holds a promising key to unlocking new doors in the treatment of kidney disease. With each study and trial, we step closer to a world where kidney disease is no longer a life sentence but a treatable condition, thanks to pioneers like Dr. David Greene.
Telehealth Psychology Building Trust with Clients.pptxThe Harvest Clinic
Telehealth psychology is a digital approach that offers psychological services and mental health care to clients remotely, using technologies like video conferencing, phone calls, text messaging, and mobile apps for communication.
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
Defecation
Normal defecation begins with movement in the left colon, moving stool toward the anus. When stool reaches the rectum, the distention causes relaxation of the internal sphincter and an awareness of the need to defecate. At the time of defecation, the external sphincter relaxes, and abdominal muscles contract, increasing intrarectal pressure and forcing the stool out
The Valsalva maneuver exerts pressure to expel faeces through a voluntary contraction of the abdominal muscles while maintaining forced expiration against a closed airway. Patients with cardiovascular disease, glaucoma, increased intracranial pressure, or a new surgical wound are at greater risk for cardiac dysrhythmias and elevated blood pressure with the Valsalva maneuver and need to avoid straining to pass the stool.
Normal defecation is painless, resulting in passage of soft, formed stool
CONSTIPATION
Constipation is a symptom, not a disease. Improper diet, reduced fluid intake, lack of exercise, and certain medications can cause constipation. For example, patients receiving opiates for pain after surgery often require a stool softener or laxative to prevent constipation. The signs of constipation include infrequent bowel movements (less than every 3 days), difficulty passing stools, excessive straining, inability to defecate at will, and hard feaces
IMPACTION
Fecal impaction results from unrelieved constipation. It is a collection of hardened feces wedged in the rectum that a person cannot expel. In cases of severe impaction the mass extends up into the sigmoid colon.
DIARRHEA
Diarrhea is an increase in the number of stools and the passage of liquid, unformed feces. It is associated with disorders affecting digestion, absorption, and secretion in the GI tract. Intestinal contents pass through the small and large intestine too quickly to allow for the usual absorption of fluid and nutrients. Irritation within the colon results in increased mucus secretion. As a result, feces become watery, and the patient is unable to control the urge to defecate. Normally an anal bag is safe and effective in long-term treatment of patients with fecal incontinence at home, in hospice, or in the hospital. Fecal incontinence is expensive and a potentially dangerous condition in terms of contamination and risk of skin ulceration
HEMORRHOIDS
Hemorrhoids are dilated, engorged veins in the lining of the rectum. They are either external or internal.
FLATULENCE
As gas accumulates in the lumen of the intestines, the bowel wall stretches and distends (flatulence). It is a common cause of abdominal fullness, pain, and cramping. Normally intestinal gas escapes through the mouth (belching) or the anus (passing of flatus)
FECAL INCONTINENCE
Fecal incontinence is the inability to control passage of feces and gas from the anus. Incontinence harms a patient’s body image
PREPARATION AND GIVING OF LAXATIVESACCORDING TO POTTER AND PERRY,
An enema is the instillation of a solution into the rectum and sig
We understand the unique challenges pickleball players face and are committed to helping you stay healthy and active. In this presentation, we’ll explore the three most common pickleball injuries and provide strategies for prevention and treatment.
3. Addendum to the NHRA
• ABF Continues until 2020
• Commonwealth growth capped at 6.5% (price +
volume)
• Reforms to improve efficiency of public hospitals:
‒Healthcare homes
‒Safety and quality considerations
‒Avoidable readmissions
‒Potentially preventable admissions
• New agreement beyond 2020 agreed by 2018
3 www.ihpa.gov.au
4. Strategic intent of ABF
• Transparency
• Value for money
• Independence
• National comparability
• Technical Efficiency
4
5. About IHPA
• Independent of all governments
‒Can not be directed on pricing
• Governed by a 9 member board
• 28 member clinical advisory committee
‒Senior medical, nursing and allied health
• 40 staff
‒Data management, statistical, classification, policy
and comms
• Strong consultation and transparency agenda
5
6. IHPA’s functions
•Set the National Efficient Price
•Classification systems
•Data standards
•Cross border and cost shifting disputes
6
7. Progress so far
• ABF
‒Admitted Acute
‒Subacute
‒Emergency
‒Non-admitted
• Block Funding
‒Community Mental Health
‒Teaching, training and
research
‒Small rural and remote
hospitals
7
9. Benchmarking portal
•ABF generates masses of data
‒ Cost data collection >1,000,000,000
records
•Used properly this data can help improve
the efficiency of hospitals by reducing
variation
•Have to make it accessible at the
hospital level!
14. Premise
• Australian and international costing studies estimate that adverse
events explain between 12.0% and 16.5% of total costs
• ICD-10-AM data is a rich source of safety and quality data,
currently underutilised
• Literature review:
‒ Good evidence that the provision of timely clinical information to
clinicians & managers leads to improvements in patient
outcomes
• Pricing signals:
‒ Provide clear sign that government values safety and quality
‒ Promote discussion of safety and quality systems amongst
clinicians AND managers
14
15. Approach
• Three areas of focus:
‒Sentinel Events
‒Hospital Acquired Complications
‒Avoidable readmissions
• Data provision to clinicians and managers a critical
component of work
15
16. Sentinel Events
16
1. Procedures involving the wrong patient or body part resulting in death or major
permanent loss of function
2. Suicide of a patient in an inpatient unit
3. Retained instruments or other material after surgery requiring re-operation or
further surgical procedure
4. Intravascular gas embolism resulting in death or neurological damage
5. Haemolytic blood transfusion reaction resulting from ABO incompatibility
6. Medication error leading to the death of a patient reasonably believed to be due
to incorrect administration of drugs
7. Maternal death associated with pregnancy, birth and the puerperium
8. Infant discharged to the wrong family
17. Sentinel Events
• From 1 July 2017 no funding for episodes of care with
a sentinel event
• ~100 events per annum (public hospitals)
• Funding impact ~$5 million per annum
17
18. Hospital Acquired Complications
• Coded data differentiates between conditions present on
admission, and those arising during admission
• Measured using CHADx system:
‒ Too much noise
‒ No measure of preventability
• Hospital Acquired Complications:
‒ Developed by clinicians
• Clear criteria:
‒ Preventability
‒ Patient Impact
‒ Cost Impact
‒ Clinical priority
18
19. 19
Pressure injury Gastrointestinal bleeding
Falls resulting in fracture and intracranial
injury
Medication complications
Healthcare associated infection Delirium
Surgical complications requiring
unplanned return to theatre
Persistent incontinence
Unplanned Intensive Care Unit
admission
Malnutrition
Respiratory complications Cardiac complications
Venous thromboembolism Third and fourth degree perineal
laceration during delivery
Renal failure Birth trauma
Hospital Acquired Complications
20. HACs add cost
20
HAC
Incremental
cost
All HACs 8.6%
Pressure injury 13.8%
Falls resulting in fracture or other intracranial injury 1.7%
Healthcare associated infection 8.8%
Surgical complications requiring unplanned return to theatre 10.9%
Unplanned intensive care unit admission
Respiratory complications 15.9%
Venous thromboembolism 12.4%
Renal failure 21.7%
Gastrointestinal bleeding 10.0%
Medication complications 8.2%
Delirium 9.8%
Persistent incontinence 2.3%
Malnutrition 7.4%
Cardiac complications 11.3%
Perineal laceration 23.2%
Neonatal birth trauma 10.8%
24. Risk Adjustment Critical
• Patient risk factors:
‒Age
‒DRG
‒Charlson Complexity Score (predicts the one year
mortality for a patient with a range of specific
comorbidities)
‒ICU admission
‒Emergency admission
• Can calculate risk score for every patient
24
27. Preventable Readmissions
• All admissions are currently paid for
• Some evidence of preventable readmissions in system
• Currently no nationally agreed, clinically acceptable list
of readmission causes
• List currently being developed – clinically led, data
driven project
• Possible inclusions:
‒Preventable hospitalisations
‒Readmission for HACs
‒Constipation
27